4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) have been assigned a consensus rating of “Moderate Buy” from the ten ratings firms that are presently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have given a buy rating to the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $33.25.

Several equities analysts have issued reports on FDMT shares. Leerink Partners reissued an “outperform” rating and issued a $17.00 price objective on shares of 4D Molecular Therapeutics in a research note on Friday, October 31st. Weiss Ratings reiterated a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research note on Wednesday, January 21st. Wall Street Zen downgraded shares of 4D Molecular Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, December 6th. Barclays initiated coverage on 4D Molecular Therapeutics in a report on Wednesday, January 28th. They issued an “overweight” rating and a $33.00 price objective on the stock. Finally, Royal Bank Of Canada reissued an “outperform” rating on shares of 4D Molecular Therapeutics in a research note on Wednesday, January 7th.

4D Molecular Therapeutics Trading Up 1.0%

4D Molecular Therapeutics stock opened at $9.08 on Thursday. 4D Molecular Therapeutics has a twelve month low of $2.23 and a twelve month high of $12.34. The stock has a 50 day moving average of $8.74 and a two-hundred day moving average of $8.53. The stock has a market capitalization of $518.74 million, a price-to-earnings ratio of -2.42 and a beta of 3.01.

4D Molecular Therapeutics (NASDAQ:FDMT) last released its earnings results on Monday, November 10th. The company reported ($1.01) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.02) by $0.01. 4D Molecular Therapeutics had a negative return on equity of 47.27% and a negative net margin of 174,314.17%.The business had revenue of $0.09 million for the quarter, compared to analyst estimates of $0.40 million. Equities analysts predict that 4D Molecular Therapeutics will post -2.84 earnings per share for the current year.

Institutional Investors Weigh In On 4D Molecular Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the business. Dynamic Technology Lab Private Ltd acquired a new position in shares of 4D Molecular Therapeutics during the 1st quarter worth $39,000. Wexford Capital LP purchased a new stake in 4D Molecular Therapeutics during the third quarter worth about $41,000. Los Angeles Capital Management LLC acquired a new position in 4D Molecular Therapeutics during the second quarter worth about $42,000. Quadrature Capital Ltd purchased a new position in 4D Molecular Therapeutics in the second quarter valued at about $42,000. Finally, Farther Finance Advisors LLC lifted its position in shares of 4D Molecular Therapeutics by 117.4% during the 3rd quarter. Farther Finance Advisors LLC now owns 4,952 shares of the company’s stock valued at $43,000 after acquiring an additional 2,674 shares during the period. Institutional investors and hedge funds own 99.27% of the company’s stock.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.